Freenome, an early cancer detection company developing blood-based screening tests, today is reporting the improved clinical performance of an updated version of its SimpleScreen™ CRC test. In data ...
MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...
Two noninvasive screening tests appeared to be effective in detecting colorectal cancer in an average-risk population, two trials suggested. In the BLUE-C trial, a next-generation multi-target stool ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Negative predictive value for nonadvanced colorectal ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “More than three out of four Americans who die from ...
Early recognition of sepsis remains challenging given heterogeneity in presentation. Existing screening tools have not yet ...
Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...
The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.
Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...
WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback